Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Hui Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, Jili…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jilin Provincial Department of Science and Technology.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The necessity of platinum-doublet chemotherapy in first-line immunotherapy for non-squamous non-small cell lung cancer (nsqNSCLC) with programmed death-ligand 1 (PD-L1) expression on less than 50% of tumor cells remains poorly investigated. Biomarkers predicting this necessity can guide chemotherapy-free treatment to minimize unnecessary toxicity.
Methods
Treated with immune checkpoint inhibitor monotherapy (ICI-mono), chemotherapy, or combination (ICI-chemo), 790 low PD-L1-expressing nsqNSCLCs (in-house: n=83; public: n=707) were analyzed for development and validation of the interaction score for additional chemotherapy (ISAC). Transcriptomic (public, n=11) and multiplex immunofluorescence data (in-house, n=100) were analyzed to evaluate the immune microenvironment.
Results
ICI-chemo, compared with ICI-mono, tended to prolong progression-free survival (PFS; HR=0.72, p=0.004) and overall survival (OS; HR=0.77, p=0.071) as first-line therapy in low PD-L1-expressing nsqNSCLCs. The added value of chemotherapy was observed in the ISAC-low subgroup (PFS: HR=0.48, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, Jilin, China.
- Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, Jilin, China.
- Oncology Department, Jilin Cancer Hospital, Changchun, Jilin, China.
- Burning Rock Biotech, Guangzhou, Guangdong, China.
- Postdoctoral Research Workstation, Jilin Cancer Hospital, Changchun, Jilin, China.
- Burning Rock Biotech, Guangzhou, Guangdong, China shangli.cai@brbiotech.com jl.cheng@163.com.
ORCID-Profile: Xinyue Wang, Ying Cheng
Förderung
- Jilin Provincial Department of Science and Technology
Zitieren
APA
Li, H., Liu, J., Zhang, L., Xu, Y., Wang, X., Lan, S., Cui, P., Wang, G., Cai, S., & Cheng, Y. (2024). Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009693
Vancouver
Li H, Liu J, Zhang L, Xu Y, Wang X, Lan S, et al. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009693
BibTeX
@article{Li2024,
author = {Li, Hui and Liu, Jingjing and Zhang, Liang and Xu, Yu and Wang, Xinyue and Lan, Shaowei and Cui, Peng and Wang, Guoqiang and Cai, Shangli and Cheng, Ying},
title = {Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009693}
}
EUVIMED